Annual report pursuant to Section 13 and 15(d)

Restructuring Charges

v2.4.1.9
Restructuring Charges
12 Months Ended
Dec. 31, 2014
Restructuring Charges [Abstract]  
Restructuring Charges
5. Restructuring Charges

In January 2012, the Company implemented a streamlining of operations, which resulted in a restructuring plan designed to sharpen its focus on value-creating opportunities led by gevokizumab and its unique antibody discovery and development capabilities. The restructuring plan included a reduction of XOMA’s personnel by 84 positions, or 34%. These staff reductions resulted primarily from the Company’s decisions to utilize a contract manufacturing organization for Phase 3 and commercial antibody production, and to eliminate internal research functions that are non-differentiating or that can be obtained cost effectively by contract service providers.

In 2014, 2013 and 2012, the Company incurred $0.1 million, $0.3 million and $4.9 million, respectively in restructuring charges related to facility costs.

The outstanding restructuring liabilities are included in accrued and other liabilities and on the accompanying consolidated balance sheets and are based upon restructuring charges recognized as of December 31, 2014 and 2013 in connection with the Company’s restructuring plans. As of December 31, 2014 and 2013, the components of these liabilities are shown below (in thousands):
   
Facility Charges (1)
 
Balance at December 31, 2013
 
$
21
 
Restructuring charges
   
84
 
Cash payments
   
(128
)
Adjustments
   
23
 
Balance at December 31, 2014
 
$
-
 

 
 
Facility Charges (1)
 
Balance at December 31, 2012
 
$
75
 
Restructuring charges
   
328
 
Cash payments
   
(434
)
Adjustments
   
52
 
Balance at December 31, 2013
 
$
21
 

(1) Includes moving and relocation costs, and lease payments, net of sublease payments.